Emerging trends in pharmaceutical design and drug manufacturing are shifting toward presenting the market with new ways to develop medications. Specialty medications continue to be a major area of pharmaceutical development and have become widely discussed in workers’ comp due to their significant costs. Although they represent approximately 1% of drug utilization, they account for nearly 7% of prescription drug costs and represent the fastest-growing segment of the U.S. pharmaceutical market. While specialty drug products are often associated with a hefty price tag, some can offer clinical advantages when deployed for the right patient at the right time, making careful oversight and patient selection imperative to achieving desired outcomes in this space. Watch the video blog to learn more.
More stories
Fewer Prescriptions, Bigger Price Tags
Prescription utilization in workers’ comp continues to decline, but that doesn’t mean drug costs are no longer a concern. In fact, the latest Enlyte Drug Trends Report finds a small number of high-cost prescriptions are creating an outsized impact. In today’s Enlyte Envision podcast, Brian Allen explores what’s driving these costs, how some providers are exploiting gaps in the system and what states can do to rein in abusive pricing.
Accurate job descriptions aid return to work
Business Insurance highlights Tammy Bradly’s insights on how accurate job descriptions help case managers support safer, more successful return-to-work plans and reduce litigation risk.
A Job Title Is Not a Return-to-Work Plan
Comprehensive job analysis and physical demands analysis help support a safe and sustained return to work.
Louisiana SB 408—A Workers’ Comp Carrier Guide to Changing Requirements
For decades, Louisiana's workers’ compensation system has stood out for its stability, with employers, insurers and injured employees operating within a well-established and largely predictable framework. Not perfect but familiar enough that most organizations knew what to expect. That changed with the passage of SB 408 (Act No. 766, 2026 Regular Session).
Plugged-In: EV Collision Insights Q2 2026
Among repairable claims, the gap in average severity between battery electric vehicles (BEVs) and gasoline-powered automobiles narrowed to a record low, although BEVs remain more costly to repair. In the United States, average severity was $5,684 for BEVs compared to $5,022 for plug-in hybrid electric vehicles (PHEVs), $5,033 for mild hybrid electric vehicles (MHEVs) and $4,955 for vehicles with an internal combustion engine (ICE). A similar trend emerged in Canada with severity of $6,645 (CAD) for BEVs, $6,227 (CAD) for PHEVs, $6,080 (CAD) for MHEVs and $5,411 (CAD) for ICE automobiles.
Claims Severity Gap Between Repairable BEVs and ICE Vehicles Hits Record Low
Mitchell today released its latest Plugged-In: EV Collision Insights report. This quarter’s report reveals that the gap in average claims severity between repairable battery electric vehicles (BEVs) and internal combustion engine (ICE) automobiles has reached its lowest level on record in both the U.S. and Canada. With a gap of just $729 in the U.S. last quarter, average repairable severity for BEVs was $5,684 compared to $4,955 for ICE alternatives.